Tin tức & Cập nhật

48-week data ASSERT odevixibat’s role in ALGS

29 May 2024 bởi

Pooled analysis of the ASSERT and ASSERT-EXT studies show sustained improvements in multiple parameters with odevixibat in individuals with Alagille syndrome (ALGS), thus reinforcing its role in the treatment of this multisystem genetic disorder.

48-week data ASSERT odevixibat’s role in ALGS

29 May 2024

Dupilumab sustains histological remission in children with EoE

29 May 2024 bởi

Treatment with higher-dose dupilumab results in sustained improvements in histologic and endoscopic measures of eosinophilic esophagitis (EoE) in children, regardless of prior use of swallowed topical corticosteroids (STCs), according to a subanalysis presented at ESPGHAN 2024.

Dupilumab sustains histological remission in children with EoE

29 May 2024

Metformin plus liraglutide eases glycemia but not gluconeogenesis in youth-onset T2D

28 May 2024

Use of metformin with or without liraglutide results in improved glycaemia but falls short of suppressing the high rates of gluconeogenesis in patients with youth-onset type 2 diabetes (Y-T2D), reports a study.

Metformin plus liraglutide eases glycemia but not gluconeogenesis in youth-onset T2D

28 May 2024

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

28 May 2024 bởi

Treatment with dupilumab substantially improves symptoms, quality of life, and other outcomes in patients with atopic hand and foot dermatitis (H/F AD), with an acceptable safety profile, results of a study have shown.

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

28 May 2024

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024 bởi

Maralixibat may have a role in treating a broader profile of children with PFIC, including those who have had biliary diversion surgery and those with MDR3 deficiency, suggest subgroup analyses from the phase III MARCH/MARCH-ON trials

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024

Original New Drug Application Approvals by US FDA (1-15 May 2024)

27 May 2024

New drug applications approved by US FDA as of 1-15 May 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2024)

27 May 2024

Ustekinumab dose intensification effective at achieving remission in certain IBD patients

26 May 2024 bởi

Two-thirds of patients with IBD treated at an IBD centre in Singapore required dose intensification (DI) while on ustekinumab, with over one-third of them achieving disease remission at 1 year, as shown in a retrospective observational study

Ustekinumab dose intensification effective at achieving remission in certain IBD patients

26 May 2024

Shorter antibiotic duration tied to higher mortality in infants with E. coli bacteremia

25 May 2024 bởi

Shorter course of antibiotics was associated with higher mortality rates in infants with Escherichia coli (E. coli) bacteremia who did not undergo a cerebrospinal fluid (CSF) evaluation compared with longer antibiotic courses, according to a recent study presented at PAS 2024.

Shorter antibiotic duration tied to higher mortality in infants with E. coli bacteremia

25 May 2024

Bisoprolol does not prevent COPD flare-ups

24 May 2024

The use of bisoprolol does not appear to yield reductions in the number of self-reported chronic obstructive pulmonary disease (COPD) exacerbations requiring treatment with oral corticosteroids, antibiotics, or both, as shown in the placebo-controlled Bisoprolol in COPD Study (BICS).

Bisoprolol does not prevent COPD flare-ups

24 May 2024

Gepotidacin as good as current standard treatment for urogenital gonorrhoea

24 May 2024 bởi

The oral investigational antibiotic gepotidacin is noninferior to the current standard treatment for uncomplicated urogenital gonorrhoea in the randomized, multicentre, phase III EAGLE-1 trial.

Gepotidacin as good as current standard treatment for urogenital gonorrhoea

24 May 2024

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

48-week data ASSERT odevixibat’s role in ALGS

48-week data ASSERT odevixibat’s role in ALGS

Dupilumab sustains histological remission in children with EoE

Dupilumab sustains histological remission in children with EoE

Metformin plus liraglutide eases glycemia but not gluconeogenesis in youth-onset T2D

Metformin plus liraglutide eases glycemia but not gluconeogenesis in youth-onset T2D

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

Maralixibat may benefit certain subgroups of children with PFIC

Maralixibat may benefit certain subgroups of children with PFIC

Original New Drug Application Approvals by US FDA (1-15 May 2024)

Original New Drug Application Approvals by US FDA (1-15 May 2024)

Ustekinumab dose intensification effective at achieving remission in certain IBD patients

Ustekinumab dose intensification effective at achieving remission in certain IBD patients

Shorter antibiotic duration tied to higher mortality in infants with E. coli bacteremia

Shorter antibiotic duration tied to higher mortality in infants with E. coli bacteremia

Bisoprolol does not prevent COPD flare-ups

Bisoprolol does not prevent COPD flare-ups

Gepotidacin as good as current standard treatment for urogenital gonorrhoea

Gepotidacin as good as current standard treatment for urogenital gonorrhoea